Kahn Swick & Foti Launches Probe into AtaiBeckley Acquisition

The investigation, led by former Louisiana Attorney General Charles C. Foti, Jr., focuses on the adequacy of the $9.25 maximum potential payout—a structure contingent upon specific regulatory milestones for the BPL-003 and VLS-01 drug programs. KSF is currently reviewing the procedural integrity of the sale to determine if the board of directors fulfilled its fiduciary duties to stakeholders or if the offer significantly undervalues the enterprise.

Investors concerned about the fairness of the transaction are encouraged to contact Managing Partner Lewis S. Kahn to discuss potential legal recourse. The firm is evaluating whether the deal process prioritized shareholder value or if the terms unfairly limit the upside for those holding ATAI stock as the company moves toward these development benchmarks.